The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

We’ve seen the first AI-generated commercials, songs and even social media influencers outside of healthcare. Will pharma be ...

Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

Chinese companies are no longer just powering the pharma industry from behind the scenes, or solely churning out “me too” ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

Join us on the Sun Pharma Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock.

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Indian pharma eyes promising prospects with needle-free drug delivery transforming patient safety & comfort: Nandita Vijayasimha, Bengaluru Tuesday, January 6, 2026, 09:00 Hrs [IS ...

India’s pharmaceutical exports reached $30.47 billion in FY 2024–25, registering a 9.4 per cent year-on-year growth, and are ...